{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-088428","form_type":"8-K","ticker":"ASTH","cik":"0001083446","company_name":"Astrana Health, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.100517+00:00","generated_at":"2026-06-12T03:44:07.654221+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ApolloMed Q2 revenue $348.2M (+29% YoY); adj. EBITDA $35.8M (+44%); reaffirms FY23 guidance","bullets":["Revenue $348.2M (+29% YoY); Care Partners revenue $325.2M (+32%); net income $13.2M (+10%).","Adjusted EBITDA $35.8M (+44% YoY); reaffirms FY23 guidance: revenue $1.3-1.5B, Adj. EBITDA $120-160M.","Recent deals: entered agreement to acquire Texas Independent Providers (120+ PCPs); formed partnership with IntraCare (425+ providers) with $25M convertible note.","Tax restatement for 2020-2022 related to intercompany dividends; no impact on revenue, EBITDA, or past/forward periods.","Cash and investments $297.7M; total stockholders' equity $566M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-088428","json":"https://secwatch.observer/filing/0001104659-23-088428.json","markdown":"https://secwatch.observer/filing/0001104659-23-088428.md","text":"https://secwatch.observer/filing/0001104659-23-088428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923088428/0001104659-23-088428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923088428/tm2323017d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:44:07.654221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"708c81dceee50690976c9cd22df18239d2950564","claim":"Astrana Health, Inc. reported three and six months ended June 30, 2023 results: revenue $348.2 million, net income $13.2 million. Guidance reaffirmed.","evidence_excerpt":"full-year 2023.” Financial Highlights for Second Quarter Ended June 30, 2023: All comparisons are to the quarter ended June 30, 2022 unless otherwise stated. • Total revenue of $348.2 million, up 29% from $269.7 million • Care Partners revenue of $325.2 million, up 32% from $247.3 million • Net income attributable to ApolloMed of $13.2 million, up 10% from $12.0","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1083446/000110465923088428/0001104659-23-088428-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and six months ended June 30, 2023"},{"label":"Revenue","value":"$348.2 million"},{"label":"Net income","value":"$13.2 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}